No, Normal Blood Pressure Does NOT Eliminate the Increased Stroke Risk of Tibolone in Women Over 60
Women over 60 years taking tibolone face an increased risk of stroke regardless of their blood pressure status. The evidence clearly demonstrates that tibolone increases stroke risk in older women with osteoporosis, and this risk is independent of baseline cardiovascular risk factors including hypertension.
The Evidence on Tibolone and Stroke Risk in Older Women
The Endocrine Society guidelines explicitly state that tibolone is not approved for osteoporosis treatment specifically because of the increased risk of stroke in older women with osteoporosis initiating therapy at ages ≥60 years 1. This recommendation is based on a landmark randomized controlled trial that was stopped early due to safety concerns.
Key Trial Findings
The pivotal RCT in older women with osteoporosis (mean age >60 years) demonstrated:
- More than doubled stroke risk: Hazard ratio 2.19 (95% CI: 1.14-4.23) 2
- The trial was stopped prematurely in February 2006 specifically due to this increased stroke risk 2
- This occurred despite the study population being selected for osteoporosis, not cardiovascular disease
Why Blood Pressure Status Doesn't Matter
The 2019 Endocrine Society osteoporosis guideline specifies that tibolone should only be considered in women who meet ALL of the following criteria 3:
- Under 60 years of age or <10 years past menopause
- Low risk of DVT
- Without prior myocardial infarction or stroke or high risk for cardiovascular disease
- Without breast cancer
Notably, the guideline does not distinguish between normotensive and hypertensive women over 60—the age cutoff itself is the critical factor. The stroke risk appears to be related to age and possibly endothelial vulnerability in older women, not simply baseline blood pressure.
Understanding the Stroke Risk Mechanism
Recent research confirms this age-related vulnerability:
- A 2025 Korean nationwide cohort study found that current tibolone users had a 3.52-fold increased risk of ischemic stroke (HR: 3.52,95% CI: 2.05-6.03) 4
- Importantly, this risk returned to baseline after discontinuation, suggesting a direct pharmacologic effect rather than selection of high-risk patients 4
The Women's Health Initiative data further demonstrates that older women (mean age 63 years) with even pre-hypertension had a 93% increased stroke risk versus normotensive women 5. This underscores that in older women, the threshold for stroke risk is lower, and adding tibolone—which independently increases stroke risk—compounds this vulnerability.
Clinical Implications
For Women Over 60 on Tibolone:
- Discontinue tibolone regardless of blood pressure control
- The stroke risk is not mitigated by normotensive status
- Consider alternative therapies for menopausal symptoms or osteoporosis (bisphosphonates, denosumab, selective estrogen receptor modulators)
Common Pitfall to Avoid:
Do not assume that good blood pressure control provides protection against tibolone-related stroke risk. The mechanism appears independent of traditional cardiovascular risk factors, likely related to direct vascular effects in aging endothelium.
The Age-60 Threshold:
The guidelines consistently use age 60 (or <10 years from menopause) as the cutoff because:
- Vascular aging accelerates after this point
- Endothelial function declines
- The risk-benefit ratio for hormone-based therapies fundamentally shifts
Alternative Approaches for Women Over 60
For menopausal symptoms: Consider non-hormonal options (SSRIs, gabapentin, clonidine) or very low-dose estrogen therapy if within 10 years of menopause and no contraindications 1.
For osteoporosis: First-line agents should be bisphosphonates or denosumab, which have proven fracture reduction without the stroke risk 3.
The evidence is unequivocal: age over 60 is itself the contraindication for tibolone use due to stroke risk, independent of blood pressure status 1, 3, 1, 3, 2.